Payment overview · 2025
General Payments
$561.23
36 reported records · 13 companies
Healthcare provider profile · identity verified
Thuresa S. Cash, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WHITLEY CITY, KY · NPI 1659511103
Verified facts
What the public records show
CMS Open Payments records show Thuresa S. Cash, APRN received $561.23 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $215.83 | 38.5% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.91 | 9.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.48 | 7.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.62 | 7.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.76 | 6.9% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $36.45 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.41 | 6.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.87 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.17 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.90 | 2.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.41 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.78 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.64 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.23 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.69 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $103.14 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.59 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.91 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.48 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.76 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 97 |
| Montelukast Sodium | Montelukast Sodium | 380 | 96 |
| Omeprazole | Omeprazole | 379 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 377 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 90 |
| Gabapentin | Gabapentin | 235 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 60 |
| Furosemide | Furosemide | 194 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 57 |
| Metformin Hcl | Metformin Hcl | 191 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 62 |
| Lisinopril | Lisinopril | 162 | 59 |
| Ozempic | Semaglutide | 152 | 32 |
| Sertraline Hcl | Sertraline Hcl | 146 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 139 | 27 |
| Bupropion Xl | Bupropion Hcl | 128 | 32 |
| Tramadol Hcl | Tramadol Hcl | 125 | 45 |
| Potassium Chloride | Potassium Chloride | 123 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 121 | 34 |
| Losartan Potassium | Losartan Potassium | 115 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 33 |
| Clonazepam | Clonazepam | 109 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 29 |
| Carvedilol | Carvedilol | 97 | 22 |
| Famotidine | Famotidine | 96 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 88 | 25 |
| Pregabalin | Pregabalin | 88 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 28 |
| Mounjaro | Tirzepatide | 83 | 16 |
| Simvastatin | Simvastatin | 83 | 21 |
| Fluconazole | Fluconazole | 80 | 42 |
| Methocarbamol | Methocarbamol | 80 | 21 |
| Eliquis | Apixaban | 79 | 25 |
| Gemfibrozil | Gemfibrozil | 78 | 24 |
| Nifedipine Er | Nifedipine | 77 | 18 |
| Prednisone | Prednisone | 77 | 49 |
| Glipizide Er | Glipizide | 76 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 58 |
| Meloxicam | Meloxicam | 74 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 13 |
| Lorazepam | Lorazepam | 69 | 19 |
| Trazodone Hcl | Trazodone Hcl | 69 | 18 |
| Buspirone Hcl | Buspirone Hcl | 68 | 19 |
| Ibuprofen | Ibuprofen | 68 | 27 |
| Doxepin Hcl | Doxepin Hcl | 63 | 13 |
| Vraylar | Cariprazine Hcl | 61 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 16 |
| Alprazolam | Alprazolam | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 16 |
| Metformin Hcl Er | Metformin Hcl | 55 | 14 |
| Amoxicillin | Amoxicillin | 54 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 20 |
| Allopurinol | Allopurinol | 52 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 13 |
| Ezetimibe | Ezetimibe | 49 | 14 |
| Glipizide | Glipizide | 49 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 13 |
| Spironolactone | Spironolactone | 47 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Azithromycin | Azithromycin | 42 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 14 |
| Linzess | Linaclotide | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 30 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 25 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | 11 |
| Baclofen | Baclofen | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 13 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 20 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.23 · 36 records | ABBVIE INC. | ARISTADA, Auvelity, CAPLYTA, FANAPT, LEQVIO, LYBALVI, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, QULIPTA, REPATHA, REXULTI, Spinosad, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error